Dr. Vinks is a prominent pediatric and adult clinical pharmacologist with experience in population PK/PD and model-informed precision dosing. His leadership as Partner will further expand the services and support we provide to companies developing therapies for pediatric and adult populations.
WASHINGTON (PRWEB)
March 22, 2023
NDA Partners’ Vice President and General Manager, Eric Fish, announced today that Alexander (Sander) A. Vinks, PhD, PharmD, FCP, a prominent pediatric and adult clinical pharmacologist and pediatric clinical trials expert, has been appointed as Partner in the firm.
Dr. Vinks joins as Partner to lead the firm’s Pediatric Drug Development Practice and further expand the clinical pharmacology and clinical trial design services within NDA Partners. He has more than 35 years of experience in clinical pharmacology, population pharmacokinetics/pharmacodynamics (PK/PD), pharmacometric modeling and simulation, and model-informed precision dosing (MIPD) and has worked with the firm as an Expert Consultant since 2017.
According to Dr. Carl Peck, Manager of NDA Partners’ drug development practice, “Dr. Vinks is a prominent clinical pharmacologist with experience in pediatric and adult clinical pharmacology, population PK/PD, pharmacometric modeling and simulation, and model-informed precision dosing. His knowledge and expertise have been highly valued by our clients, and his leadership as Partner will further expand the services and support we provide to companies developing therapies for pediatric and adult populations.”
Dr. Vinks formerly served as the Cincinnati Children’s Research Foundation Endowed Chair and Director of the Division of Clinical Pharmacology, in addition to the Principal Investigator of the National Institute of Child Health and Human Development (NICHD) Pediatric Pharmacology Research Unit (PPRU) network site at Cincinnati Children’s Hospital Medical Center. He also directed the multidisciplinary Pharmacometrics Center of Excellence and was co-director of the Cincinnati Children’s Genetic Pharmacology Service. Dr. Vinks currently serves is Professor Emeritus at the University of Cincinnati, College of Medicine and as an advisor on the FDA sub-committee for Pharmaceutical Science and Clinical Pharmacology.
Dr. Vinks received his PhD and MS (Doctorandus) in Clinical Pharmacology from Leiden University, The Netherlands, a PharmD from Leiden University and the Royal Dutch Pharmacists Association (KNMP), and a master’s degree in pharmacology from the University of Toronto. He is board certified in clinical pharmacology and is a fellow of the American College of Clinical Pharmacology.
About NDA Partners
NDA Partners, a ProPharma company, is a life sciences management consulting and contract development organization focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Expert Consultants in NDA Partners include three former FDA Center Directors; the former Chief Executive Officer and Chief Science Officer at the United States Pharmacopeial Convention (USP); an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, product development program design and management, expert consulting, functional teams, project-based solutions, and clinical trial design and management.
Contact
Eric Fish, Vice President & General Manager
Office: 540-738-2550
FishEric@ndapartners.com
Share article on social media or email: